Nearly 30% of patients with diabetes mellitus (DM) develop diabetic nephropathy over time. The long-term effect of weight loss, through lifestyle intervention, on kidney function remains unknown.We evaluated 94 patients with obesity and DM (12.8% type 1 DM and 87.2% type 2 DM, age 53.9±9.9 years, diabetes duration 10.9±10.3 years, weight 108.0±18.8 kg, and BMI 38.1±5.0 kg/m2) who enrolled in a 12-week multidisciplinary intensive lifestyle intervention (ILI) conducted in real-world clinical practice. Patients were prospectively followed for over 15 years. At one year, we stratified participants according to their percentage weight loss into: group A, who maintained ≥7% weight loss (48.9%) and group B, who maintained <7% weight loss (51.1%). At 15 years, the full cohort maintained an average of 8.0±2.8 kg weight loss (10.1±19.6%, p<0.0001). Group A lost 12.8±4.1 kg (15.1±21.9%, p<0.0001) and group B lost 3.9±3.4 kg (5.5±17.6%, p=0.024). A1C did not change from baseline in group A, but increased in group B (0.6±0.5%, p=0.027). Systolic blood pressure did not change in both groups. Diastolic blood pressure decreased only in group A from 77±3 mmHg to 73±3 mmHg (p=0.03). LDL-cholesterol and HDL-cholesterol significantly improved in both groups, however, triglycerides significantly increased in both groups. Estimated glomerular filtration rate (eGFR) increased in group A from 79.5±12.5 to 92.5±15.3 mL/min/1.73 m2 (p=0.02) and in group B from 80.5±7.5 to 90.8±13.3 mL/min/1.73 m2 (p=0.02). There was no significant change in urinary albumin/creatinine ratio from baseline or serum creatinine in both groups.We conclude that 12 weeks of ILI have a sustained improvement of renal function for up to 15 years after intervention. This improvement is more pronounced in those who maintained ≥7% weight loss at one year.

Disclosure

T. Salah: None. M. Al-Badri: None. A. Barbar Askar: None. A. Khater: None. S.E. Dhaver: None. A. Mottalib: None. O. Hamdy: Research Support; Eli Lilly and Company, Novo Nordisk. Consultant; Abbott Nutrition. Stock/Shareholder; Healthimation. Research Support; Gilead Sciences, Inc. Advisory Panel; Nemaura Medical, Twin Health, L-Nutra Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.